Zdrowie i gospodarka · 21/11/2017
FDA Clears Path for Vortioxetine Hydrobromide Oral Tablet Approval
The FDA has determined that TRINTELLIX (vortioxetine hydrobromide) oral tablet, equivalent to 15 milligrams base, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications.
Source: Federal Register — Food and Drug AdministrationOpen original release →